SCHEMBL10156476

SCHEMBL10156476

CNS(=O)(=O)c1ccc(N)cc1OC

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.54
RAPGEF3 O95398 1/20 0.49
GAA P10253 5/20 0.49
MAPT P10636 4/20 0.49
TSHR P16473 1/20 0.49
MAPK1 P28482 1/20 0.49
HTT P42858 1/20 0.49
ALDH1A1 P00352 2/20 0.45
PKM P14618 1/20 0.42
LMNA P02545 1/20 0.42
KDM4E B2RXH2 2/20 0.41
TRPV4 Q9HBA0 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
MMP1 P03956 1/20 0.41
MMP2 P08253 1/20 0.41
MMP9 P14780 1/20 0.41
MMP8 P22894 1/20 0.41
MMP13 P45452 1/20 0.41
MEP1B Q16820 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10641260 0.86 L3MBTL1 (0.68) L3MBTL1GAAMAPTTSHRMAPK1
SCHEMBL14930249 0.83 RAPGEF3 (0.47) RAPGEF3GAAMAPTTSHRMAPK1
SCHEMBL3467457 0.80 L3MBTL1 (0.58) L3MBTL1RAPGEF3GAAMAPTTSHR
SCHEMBL2031074 0.80 PKM (0.59) L3MBTL1RAPGEF3GAAMAPTTSHR
SCHEMBL1100517 0.80 L3MBTL1 (0.58) L3MBTL1RAPGEF3GAAMAPTTSHR
SCHEMBL31618987 0.79 ALDH1A1 (0.47) L3MBTL1RAPGEF3GAAMAPTTSHR
SCHEMBL154427 0.79 ALDH1A1 (0.51) L3MBTL1RAPGEF3GAAMAPTTSHR
SCHEMBL31618988 0.79 ALDH1A1 (0.47) L3MBTL1RAPGEF3GAAMAPTTSHR
SCHEMBL2241067 0.79 GAA (0.62) RAPGEF3GAAALDH1A1LMNACA1
SCHEMBL2241241 0.79 SMN1; SMN2 (0.59) GAAMAPK1HTTALDH1A1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10752624-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2020-08-25 US disclosed
US-20180305356-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2018-10-25 US disclosed
US-10000482-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2018-06-19 US disclosed
US-9637491-B2 Pyrazolo[4,3-D]pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-05-02 US disclosed
US-9487491-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2016-11-08 US disclosed
EP-2428508-B9 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC (JP) 2016-04-20 EP disclosed
EP-2428508-B1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC (JP) 2015-12-16 EP disclosed
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-09-24 US disclosed
US-20150259340-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-09-17 US disclosed
US-8969336-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2015-03-03 US disclosed
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2014-12-18 US disclosed
WO-2014060113-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 WO disclosed
WO-2014060112-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 WO disclosed
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND WATERS TECHNOLOGIES CORPORATION (US) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150259340-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK L3MBTL1 457/4885RAPGEF3 1244/4885GAA 742/4885
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS LRRK2, MYLK2, MYLK L3MBTL1 505/4885RAPGEF3 1056/4885GAA 940/4885
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 L3MBTL1 1714/4885RAPGEF3 1767/4885GAA 3821/4885
US-20180305356-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK L3MBTL1 457/4885RAPGEF3 1244/4885GAA 742/4885
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 L3MBTL1 1714/4885RAPGEF3 1767/4885GAA 3821/4885
US-10000482-B2 Kinase inhibitors LRRK2, MYLK2, MYLK L3MBTL1 485/4885RAPGEF3 1356/4885GAA 698/4885
US-10752624-B2 Kinase inhibitors LRRK2, MYLK2, MYLK L3MBTL1 485/4885RAPGEF3 1356/4885GAA 698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.